Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis-Reference-Cited by-同舟云学术

Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis

Published:2024-02-23 Issue:4 Volume:103 Page:1363-1372
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Teramoto Masahiro^ORCID,Tamaki Hiroya^ORCID,Kaida Katsuji,Samori Mami,Takahashi-Hirata Saki,Utsunomiya Nobuto,Katayama Atsushi,Fukunaga Keiko,Inoue Takayuki,Yoshihara Kyoko,Ikegame Kazuhiro,Okada Masaya,Yoshihara Satoshi

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05654-7.pdf

Reference41 articles.

1. Michallet M, Thomas X, Vernant JP et al (2000) Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant 26:1157–1163. https://doi.org/10.1038/sj.bmt.1702690

2. Ganzel C, Sun Z, Cripe LD et al (2018) Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol 93:1074–1081. https://doi.org/10.1002/ajh.25162

3. Begna KH, Kittur J, Gangat N et al (2022) European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. Blood Cancer J 12:7. https://doi.org/10.1038/s41408-022-00606-8

4. Price SL, Lancet JE, George TJ et al (2011) Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res 35:301–304. https://doi.org/10.1016/j.leukres.2010.09.002

5. Magenau J, Westervelt P, Khaled S et al (2017) A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 52:59–65. https://doi.org/10.1038/bmt.2016.188